***Pharmaceutical Benefits Advisory Committee***

Email: PBAC@health.gov.au Address all mail to:

 PBAC Secretariat

 GPO Box 9848

 Canberra ACT 2601

 **DELISTING OF PHARMACEUTICAL BENEFIT ITEMS**

**EFFECTIVE 01 APRIL 2024**

Following is the advice of the Pharmaceutical Benefits Advisory Committee concerning the delisting of items from the declaration under subsections 85(2) and 85(2A) of the *National Health Act* *1953*, with effect from the above date.

|  |  |
| --- | --- |
| **Item** | **PBAC Advice** |
| Abacavir with lamivudine and zidovudine | The sponsor requested the delisting of Trizivir® (abacavir with lamivudine and zidovudine) from the Pharmaceutical Benefits Scheme (PBS).The PBAC noted the low number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |
| Fosamprenavir | The sponsor requested the delisting of Telzir® (fosamprenavir) from the PBS.The PBAC noted the low number of services in the last financial year and that there are suitable alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |
| Paraffin with retinol palmitate | The sponsor requested the delisting of VitA-POS® (paraffin with retinol palmitate) from the PBS.The PBAC noted the moderate number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |
| Tropisetron  | The sponsor requested the delisting of Tropisetron-AFT™ (tropisetron) from the PBS.The PBAC noted the low number of services in the last financial year and that there are multiple alternatives on the PBS. The PBAC advised the delisting of this product would not result in an unmet clinical need. |



Vanessa McMahon

Director, PBAC Assessment Section

Office of Health Technology Assessment

Technology Assessment and Access Division

20 March 2024